Developer docs
API playgroundTry for free, no card

Search company profiles

Spectrawave

Full company profile

uuid0000rd3

Namestring
Spectrawave
Legal namestring
SpectraWAVE, Inc.
Websiteurl
spectrawave.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SpectraWAVE is a U.S. medical device company that develops AI-enabled intravascular imaging and physiological assessment systems for interventional cardiology. Founded in 2017 and headquartered in Bedford, Massachusetts, the company was acquired by Royal Philips in January 2026 and now operates within Philips' Image-Guided Therapy business. Its flagship product, the HyperVue Imaging System, combines proprietary DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) on a single console, paired with the single-use Starlight Imaging Catheter (2.5 Fr, indicated for vessels 2.0–5.2 mm). The platform performs a 100 mm pullback in under one second at 120 mm/s, supports low- or no-contrast acquisition, and applies AI-powered automated image review at the bedside for lipid, calcium, EEL, lumen, and stent metrics. The X1-FFR software add-on (FDA-cleared October 2025) derives fractional flow reserve from a single angiogram without pressure wires or adenosine drugs, available exclusively on HyperVue.

The company's revenue model is a hybrid of capital equipment sales (HyperVue consoles) and recurring single-use catheter consumables (Starlight), sold through a direct enterprise field sales force targeting U.S. hospitals and cardiac catheterization labs performing percutaneous coronary interventions. Go-to-market is led by a dedicated commercial organization including a Chief Commercial Officer, VP of Sales, and VP of Strategic Accounts. Customer segments are narrowly defined as interventional cardiology departments and cath labs; the company does not publicly disclose pricing, contract structures, or named hospital customers. Strategic and financial backers historically included Johnson & Johnson Innovation (JJDC, Series B lead), Deerfield Management, S3 Ventures, Lumira Ventures, SV Health Investors, and Orchestra BioMed. Co-founders include prominent interventional cardiologists Gregg Stone (Mount Sinai), Guillermo Tearney (MGH), James Muller (Brigham & Women's), and Jeffrey O'Donnell (Runway Healthcare), lending clinical credibility and KOL access.

Short descriptiontext

SpectraWAVE, acquired by Philips in January 2026, develops the HyperVue Imaging System combining DeepOCT and NIRS intravascular imaging with the X1-FFR wire-free physiology software, sold to U.S. hospitals and cardiac catheterization labs for image-guided percutaneous coronary interventions.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intravascular imaging, coronary imaging devices, optical coherence tomography, cardiac catheterization equipment, AI medical imaging
Industry1 code
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Intravascular Imaging Systems
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Hardware Sales
TypeHardware Sales
Description

Sale of HyperVue Imaging Systems to hospitals and cardiac catheterization labs. The system includes console hardware and specialized imaging catheters (Starlight Imaging Catheter) that are used in coronary procedures.

finance.yahoo.com
2Consumables and Imaging Catheters
TypeHardware Sales
Description

Recurring revenue from single-use imaging catheters and consumables required for each procedure. The Starlight Imaging Catheter is intended for use in coronary interventions.

spectrawave.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Medical imaging system - pricing not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

No pricing information publicly available. Sales appear to be direct to healthcare facilities through enterprise contracts.

mddionline.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1HyperVue
Description

Intravascular imaging system combining DeepOCT and NIRS technologies for coronary artery disease treatment

spectrawave.com
+3 more records
Core offering1 text field

SpectraWAVE develops and sells the HyperVue Imaging System, an intravascular medical device that combines DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) to deliver comprehensive coronary artery imaging and plaque characterization during percutaneous coronary interventions. The platform is paired with the Starlight Imaging Catheter and the X1-FFR software module, which derives fractional flow reserve (FFR) from a single angiogram without wires or drugs, using AI-powered automated analysis at the bedside.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SpectraWAVE offers a unified medical device platform combining the HyperVue Imaging System as the core product with integrated X1-FFR software module. The HyperVue provides comprehensive DeepOCT+NIRS intravascular imaging for coronary artery visualization, while X1-FFR delivers angiography-derived fractional flow reserve physiology assessment. Both products are available on a single platform, enabling clinicians to perform both imaging and physiology assessments during percutaneous coronary interventions. The system features AI-powered automated analysis for fast, informed PCI decision-making.

Product and service3 records
1HyperVue Imaging System
CategoryIntravascular imaging system
Description

Intravascular imaging medical device combining DeepOCT and NIRS to image coronary arteries during percutaneous coronary interventions, indicated for patients who are candidates for transluminal interventional procedures. Provides rapid 100mm pullback acquisition in less than a second, no-flush prep catheter design, and AI-powered automated analysis at the bedside with customizable structural and compositional overlays.

2X1-FFR
CategoryCoronary physiology software
Description

AI-enabled, wire-free, drug-free fractional flow reserve software available exclusively on the HyperVue Imaging System. Derives FFR from a single angiogram within about one minute without pressure wires or adenosine, using AI-enabled vessel segmentation and hands-free angio co-registration.

3Starlight Imaging Catheter
CategoryIntravascular imaging catheter
Description

Single-use imaging catheter for use with the HyperVue Imaging System, intended for vessels 2.0 to 5.2 mm in diameter. Features a no-flush prep closed system with a low-profile 2.5 Fr design for rapid pullback acquisition. Not intended for use in target vessels that have undergone previous bypass procedures.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Royal Philips
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Royal Philips agreed to acquire SpectraWAVE in December 2025, with the acquisition completing in January 2026. The acquisition integrates SpectraWAVE's HyperVue Imaging System and X1-FFR with Philips' existing Azurion platform and IVUS technologies to enhance Philips' image-guided therapy offerings in coronary interventions.

philips.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GE HealthCare provides angiography and cardiology imaging systems that interface with intracoronary imaging and physiology devices — an adjacent incumbent in the cath-lab ecosystem.

2Abbott
TypeDirect peer
Description

Abbott markets the Ilumien Optis OCT platform and Dragonfly imaging catheter — the dominant commercial OCT competitor to SpectraWAVE's HyperVue in intracoronary imaging.

TypeEmerging player
Description

HeartFlow's FFR-CT provides non-invasive coronary physiology from CT angiography, competing for the same clinical question (do we need invasive FFR?) that X1-FFR addresses from the cath lab.

TypeDirect peer
Description

ACIST markets the Navvus microcatheter for FFR measurement and HemoSphere physiology tools — a direct competitor to SpectraWAVE's physiology offering, now part of Bracco's imaging franchise.

TypeBroad incumbent
Description

Medtronic is a broad incumbent in interventional cardiology with historical FFR offerings (acquired via RDM / legacy businesses) that overlap with the clinical use cases SpectraWAVE targets.

TypeEmerging player
Description

Elucid develops AI-based cardiovascular imaging analysis software (e.g., vascuCAP), overlapping with SpectraWAVE's AI-powered image analysis positioning in cardiac imaging informatics.

TypeEmerging player
Description

CathWorks' FFRangio computes FFR from angiograms without pressure wires — a directly competing approach to SpectraWAVE's X1-FFR, targeting the same wire-free FFR workflow.

8Royal Philips
TypeBroad incumbent
Description

Now SpectraWAVE's parent, Philips sells the Azurion platform and an existing IVUS line; SpectraWAVE's HyperVue and X1-FFR are being integrated into this broader image-guided therapy portfolio.

TypeDirect peer
Description

Boston Scientific's IVUS portfolio (OptiCross, iLab) competes head-to-head with HyperVue in cath-lab imaging and shares SpectraWAVE's interventional cardiology customer base.

TypeBroad incumbent
Description

Siemens Healthineers sells cardiology imaging systems and post-processing software used in coronary procedures; an adjacent incumbent whose installed base competes for cath-lab workflow integration.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spectrawave

Intravascular Imaging Systemsspectrawave.com

SpectraWAVE, acquired by Philips in January 2026, develops the HyperVue Imaging System combining DeepOCT and NIRS intravascular imaging with the X1-FFR wire-free physiology software, sold to U.S. hospitals and cardiac catheterization labs for image-guided percutaneous coronary interventions.

What Spectrawave does

SpectraWAVE is a U.S. medical device company that develops AI-enabled intravascular imaging and physiological assessment systems for interventional cardiology. Founded in 2017 and headquartered in Bedford, Massachusetts, the company was acquired by Royal Philips in January 2026 and now operates within Philips' Image-Guided Therapy business. Its flagship product, the HyperVue Imaging System, combines proprietary DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) on a single console, paired with the single-use Starlight Imaging Catheter (2.5 Fr, indicated for vessels 2.0–5.2 mm). The platform performs a 100 mm pullback in under one second at 120 mm/s, supports low- or no-contrast acquisition, and applies AI-powered automated image review at the bedside for lipid, calcium, EEL, lumen, and stent metrics. The X1-FFR software add-on (FDA-cleared October 2025) derives fractional flow reserve from a single angiogram without pressure wires or adenosine drugs, available exclusively on HyperVue.

The company's revenue model is a hybrid of capital equipment sales (HyperVue consoles) and recurring single-use catheter consumables (Starlight), sold through a direct enterprise field sales force targeting U.S. hospitals and cardiac catheterization labs performing percutaneous coronary interventions. Go-to-market is led by a dedicated commercial organization including a Chief Commercial Officer, VP of Sales, and VP of Strategic Accounts. Customer segments are narrowly defined as interventional cardiology departments and cath labs; the company does not publicly disclose pricing, contract structures, or named hospital customers. Strategic and financial backers historically included Johnson & Johnson Innovation (JJDC, Series B lead), Deerfield Management, S3 Ventures, Lumira Ventures, SV Health Investors, and Orchestra BioMed. Co-founders include prominent interventional cardiologists Gregg Stone (Mount Sinai), Guillermo Tearney (MGH), James Muller (Brigham & Women's), and Jeffrey O'Donnell (Runway Healthcare), lending clinical credibility and KOL access.

Spectrawave firmographics

Firmographics
Name
Spectrawave
Legal name
SpectraWAVE, Inc.
Website
https://spectrawave.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
SpectraWAVE, acquired by Philips in January 2026, develops the HyperVue Imaging System combining DeepOCT and NIRS intravascular imaging with the X1-FFR wire-free physiology software, sold to U.S. hospitals and cardiac catheterization labs for image-guided percutaneous coronary interventions.
Ownership category
akta.pro rank

Spectrawave industry classification

Industry
Product category
Intravascular Imaging Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Intravascular imaging
  • Coronary imaging devices
  • Optical coherence tomography
  • Cardiac catheterization equipment
  • AI medical imaging

Where Spectrawave is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spectrawave business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Hardware Sales: Sale of HyperVue Imaging Systems to hospitals and cardiac catheterization labs. The system includes console hardware and specialized imaging catheters (Starlight Imaging Catheter) that are used in coronary procedures.
  2. Consumables and Imaging Catheters: Recurring revenue from single-use imaging catheters and consumables required for each procedure. The Starlight Imaging Catheter is intended for use in coronary interventions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMedical imaging system - pricing not publicly disclosed

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Spectrawave product offering

Product offering

Core offering

SpectraWAVE develops and sells the HyperVue Imaging System, an intravascular medical device that combines DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) to deliver comprehensive coronary artery imaging and plaque characterization during percutaneous coronary interventions. The platform is paired with the Starlight Imaging Catheter and the X1-FFR software module, which derives fractional flow reserve (FFR) from a single angiogram without wires or drugs, using AI-powered automated analysis at the bedside.

Product overview

SpectraWAVE offers a unified medical device platform combining the HyperVue Imaging System as the core product with integrated X1-FFR software module. The HyperVue provides comprehensive DeepOCT+NIRS intravascular imaging for coronary artery visualization, while X1-FFR delivers angiography-derived fractional flow reserve physiology assessment. Both products are available on a single platform, enabling clinicians to perform both imaging and physiology assessments during percutaneous coronary interventions. The system features AI-powered automated analysis for fast, informed PCI decision-making.

Differentiator

Problem solved

Functional benefit

Brands

  • HyperVue: Intravascular imaging system combining DeepOCT and NIRS technologies for coronary artery disease treatment
  • X1-FFR
  • DeepOCT
  • Starlight

Products and services

  • HyperVue Imaging System Intravascular imaging medical device combining DeepOCT and NIRS to image coronary arteries during percutaneous coronary interventions, indicated for patients who are candidates for transluminal interventional procedures. Provides rapid 100mm pullback acquisition in less than a second, no-flush prep catheter design, and AI-powered automated analysis at the bedside with customizable structural and compositional overlays.
  • X1-FFR AI-enabled, wire-free, drug-free fractional flow reserve software available exclusively on the HyperVue Imaging System. Derives FFR from a single angiogram within about one minute without pressure wires or adenosine, using AI-enabled vessel segmentation and hands-free angio co-registration.
  • Starlight Imaging Catheter Single-use imaging catheter for use with the HyperVue Imaging System, intended for vessels 2.0 to 5.2 mm in diameter. Features a no-flush prep closed system with a low-profile 2.5 Fr design for rapid pullback acquisition. Not intended for use in target vessels that have undergone previous bypass procedures.

Companies that use Spectrawave

Customer profile

Segments2 records

Ideal customer profiles1 record

Spectrawave technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature9 records

Spectrawave partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Royal PhilipsflagshipStrategic or Co-development Partner · 15 December 2025Royal Philips agreed to acquire SpectraWAVE in December 2025, with the acquisition completing in January 2026. The acquisition integrates SpectraWAVE's HyperVue Imaging System and X1-FFR with Philips' existing Azurion platform and IVUS technologies to enhance Philips' image-guided therapy offerings in coronary interventions.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Spectrawave competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: GE HealthCare provides angiography and cardiology imaging systems that interface with intracoronary imaging and physiology devices — an adjacent incumbent in the cath-lab ecosystem.
  • Medtronic: Medtronic is a broad incumbent in interventional cardiology with historical FFR offerings (acquired via RDM / legacy businesses) that overlap with the clinical use cases SpectraWAVE targets.
  • Royal Philips: Now SpectraWAVE's parent, Philips sells the Azurion platform and an existing IVUS line; SpectraWAVE's HyperVue and X1-FFR are being integrated into this broader image-guided therapy portfolio.
  • Siemens Healthineers: Siemens Healthineers sells cardiology imaging systems and post-processing software used in coronary procedures; an adjacent incumbent whose installed base competes for cath-lab workflow integration.

Direct peers

  • Abbott: Abbott markets the Ilumien Optis OCT platform and Dragonfly imaging catheter — the dominant commercial OCT competitor to SpectraWAVE's HyperVue in intracoronary imaging.
  • ACIST Medical Systems (Bracco): ACIST markets the Navvus microcatheter for FFR measurement and HemoSphere physiology tools — a direct competitor to SpectraWAVE's physiology offering, now part of Bracco's imaging franchise.
  • Boston Scientific: Boston Scientific's IVUS portfolio (OptiCross, iLab) competes head-to-head with HyperVue in cath-lab imaging and shares SpectraWAVE's interventional cardiology customer base.

Emerging players

  • HeartFlow: HeartFlow's FFR-CT provides non-invasive coronary physiology from CT angiography, competing for the same clinical question (do we need invasive FFR?) that X1-FFR addresses from the cath lab.
  • Elucid Bioimaging: Elucid develops AI-based cardiovascular imaging analysis software (e.g., vascuCAP), overlapping with SpectraWAVE's AI-powered image analysis positioning in cardiac imaging informatics.
  • CathWorks: CathWorks' FFRangio computes FFR from angiograms without pressure wires — a directly competing approach to SpectraWAVE's X1-FFR, targeting the same wire-free FFR workflow.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Spectrawave social profiles

Digital presence

Spectrawave financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spectrawave leadership team

Management profile

Number of profiles

Profiles13 records

Spectrawave funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spectrawave M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectrawave

What does Spectrawave do?

SpectraWAVE develops and sells the HyperVue Imaging System, an intravascular medical device that combines DeepOCT (Optical Coherence Tomography) and NIRS (Near-Infrared Spectroscopy) to deliver comprehensive coronary artery imaging and plaque characterization during percutaneous coronary interventions. The platform is paired with the Starlight Imaging Catheter and the X1-FFR software module, which derives fractional flow reserve (FFR) from a single angiogram without wires or drugs, using AI-powered automated analysis at the bedside.

Is Spectrawave a public or private company?

Spectrawave is a private company. It is classified as corporate owned and is currently acquired.

When was Spectrawave founded?

Spectrawave was founded in 2017. It employs 11 to 50 people.

Where is Spectrawave based?

Spectrawave is headquartered in Bedford, United States, in the North America region.

How does Spectrawave make money?

Two revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are consumables and Imaging Catheters.

Who are Spectrawave's main competitors?

Broad incumbents on record are GE HealthCare, Medtronic, Royal Philips and Siemens Healthineers. Direct peers are Abbott, ACIST Medical Systems (Bracco) and Boston Scientific. Emerging players are HeartFlow, Elucid Bioimaging and CathWorks.

Does Spectrawave have an API?

No public API is recorded for Spectrawave.

What industry is Spectrawave in?

Spectrawave's product category is Intravascular Imaging Systems. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRadiation Dose Management Market worth $0.96 billion by 2031 - Exclusive Report by MarketsandMarkets™The radiation dose management market is projected to grow from $0.51 billion in 2026 to $0.96 billion by 2031, a CAGR of 13.3%. North America holds the largest share at 42.1% in 2025, and the cardiology segment is expected to see the highest growth. Asia Pacific is forecast to be the fastest-growing region.openPR.comUnited States Fractional Flow Reserve Market 2031 | Growth Drivers, Key Players & Investment OpportunitiesThe Global Fractional Flow Reserve Market was valued at US$ 881.35 million in 2023 and is projected to reach US$ 2,047.68 million by 2031, growing at a CAGR of 11.27% during 2024-2031. Key industry developments include Royal Philips' acquisition of SpectraWAVE Inc. in December 2025, integrating the X1-FFR AI-enabled coronary physiology platform into its cardiovascular portfolio. Japan's Ministry of Health, Labour and Welfare enabled national reimbursement for MedHub-AI's AutocathFFR system in October 2025, with the company also expanding deployment through a strategic collaboration with Terumo Corporation.LaserfocusworldPhotonics Hot List: January 16, 2026A University of Strathclyde team in the U.K. is developing affordable medical imaging tools using consumer-grade 3D printers and low-cost materials. Business headlines include VIAVI Solutions partnering with Squareroot8 on quantum security and Philips' planned acquisition of SpectraWAVE. Researchers at the University of Turku in Finland have engineered organic infrared photodiodes with built-in filtering capabilities for real-world applications.Epic-PhotonicsDecember 2025 Mergers, Acquisitions and Investment HighlightsThe photonics industry recorded 24 mergers and acquisitions and 24 investments in December 2025, with the largest deal being Marvell Technology's $3.25 billion acquisition of Celestial AI to accelerate its connectivity strategy for next-generation AI and cloud data centers. Other major transactions included CACI's $2.6 billion acquisition of ARKA for space-based sensing capabilities and Quantum Computing's $110 million purchase of Luminar Semiconductor to advance its photonic technologies roadmap. European companies were prominent in the M&A activity, with notable deals including FormFactor acquiring German pioneer Keystone Photonics and Dutch company Philips acquiring U.S.-based SpectraWAVE for AI-powered coronary imaging.Imaging Technology NewsPhilips Enters Agreement to Acquire SpectraWAVERoyal Philips has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in enhanced vascular imaging and AI-powered medical imaging technology for treating coronary artery disease. SpectraWAVE, based in Bedford, Massachusetts with over 70 employees, develops the HyperVue Imaging System and X1-FFR angiography-derived physiology solution. The acquisition will expand Philips' coronary intervention portfolio within its Azurion image-guided therapy platform, with financial terms not disclosed.Medical Device NetworkPhilips announces SpectraWAVE acquisition, expanding intravascular imaging portfolioPhilips has announced its acquisition of SpectraWAVE, thereby enhancing its intravascular imaging portfolio. This strategic move reflects Philips' commitment to advancing medical technology and improving patient care outcomes. The acquisition is expected to support further innovation in medical imaging solutions.optics.orgPhilips snaps up intravascular imaging pioneer SpectraWAVEPhilips is acquiring US medical imaging company SpectraWAVE, a deal whose terms remain undisclosed, expanding its image-guided therapy portfolio with the startup's AI-powered intravascular imaging technology. SpectraWAVE, founded in 2017 and employing 70 people, had raised $50 million in Series B funding in September 2024 led by Johnson & Johnson, and received FDA pre-market approval in 2023 for its HyperVue platform that combines optical coherence tomography with near-infrared spectroscopy for coronary artery disease treatment. Philips CEO Roy Jakobs stated the company is "doubling down on image-guided therapy" to expand its coronary intervention segment.Cardiovascular BusinessPhilips to acquire AI-enabled intravascular imaging specialists SpectraWAVERoyal Philips has agreed to acquire SpectraWAVE, a Massachusetts-based medtech company specializing in AI-enabled coronary artery disease intravascular imaging and fractional flow reserve assessment technology. SpectraWAVE, co-founded by cardiologists in 2017, developed the FDA-cleared HyperVue Imaging System and raised $50 million in 2024 with Johnson & Johnson among the investors. The acquisition strengthens Philips' presence in the cardiovascular imaging space, though financial terms have not been disclosed.MedTech DivePhilips to acquire SpectraWAVEPhilips announced its agreement to acquire SpectraWAVE, a company specializing in tools for diagnosing and treating coronary artery disease, without disclosing the deal terms. The acquisition aims to expand Philips' portfolio of intravascular imaging and physiological assessment devices. SpectraWAVE's technologies intend to enhance Philips' image-guided therapy offerings and support treatment decisions with AI-enabled solutions.MassDevicePhilips to acquire AI-powered imaging tech developer SpectrawavePhilips (NYSE: PHG) announced an agreement to acquire SpectraWave, a Bedford, Massachusetts-based developer of AI-powered Enhanced Vascular Imaging technology for coronary artery disease treatment, for undisclosed financial terms. The acquisition aims to strengthen Philips' image-guided therapy portfolio by integrating SpectraWave's HyperVue intravascular imaging system and X1-FFR angiography-derived physiology solution with its existing Azurion platform and IVUS technologies. Philips CEO Roy Jakobs stated the company is "doubling down on image-guided therapy" to expand its coronary intervention offerings and improve patient care.